Hematopoietic stem cell transplantation in multiple myeloma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 7, Issue 9, 2009, Pages 961-970

  Harousseau, Jean Luc ^a  

^a Rene Gauducheau Cancer Center   (France)

Author keywords

Allogeneic stem cell transplantation; Autologous stem cell transplantation; Bortezomib; Lenalidomide; Multiple myeloma; Thalidomide

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; THALIDOMIDE; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MORBIDITY; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REVIEW; TREATMENT RESPONSE;

EID: 72149100443     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2009.0063     Document Type: Review

References (49)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-97. (Pubitemid 26240110)
2. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883. (Pubitemid 36532313)
3. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: upfront or rescue treatment? Results of a multicenter sequential randomized trial. Blood 1998;92:3131-3136. (Pubitemid 28492319)
4. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50-70: results of a randomized controlled trial. Blood 2004;104:3052-3057.
5. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227-9233. (Pubitemid 46260178)
6. Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish Cooperative Group PETHEMA. Blood 2005;106:3755-3759. (Pubitemid 41739009)
7. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup trial S9321. J Clin Oncol 2006;24;929-936. (Pubitemid 46638847)
8. Brenner H, Gondos A, Puke S. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-2526.
9. Attal M, Harousseau JL, Facon T, et al. Intergroupe Francophone du Myelome: single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-2502.
10. Harousseau JL, Avet-Loiseau, Attal M, et al. Achieving at least very good partial remission is a simple and robust prognostic factor in patients with multiple myeloma treated with high dose therapy. Long-term analysis of IFM 99-02 and 99-104 trials. J Clin Oncol 2009; in press.
11. van de Velde HJK, Liu X, Chen G, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007;92:1399-1406 (Pubitemid 350144158)
12. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients treated with high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol 1998;102:1115-1123. (Pubitemid 28435189)
13. Durie BG, Harousseau JL, San Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473.
14. Facon T, Mary JY, Hulin C, et al. Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;307:1209-1218.
15. Harousseau JL. Role of stem cell transplantation. Hematol Oncol Clin N Am 2007;21:1157-1174.
16. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem autotransplants for newly diagnosed multiple myeloma. Blood;1999:93:55-65.
17. Cavo M, Tosi P, Zamagni E, et al. Prospective randomized study of single compared with double autologous stem cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:2434-2441. (Pubitemid 46999214)
18. Sonneveld P, van der Holt B, Segeren CM, et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term results of the Dutch Cooperative group HOVON 24 trial. Haematologica 2007;92:928-935. (Pubitemid 350144239)
19. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma : the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489-3495.
20. Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometry is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112:4017-4023.
21. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic stem cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021-1030. (Pubitemid 43357806)
22. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006;15:3289-3294.
23. Spencer A, Prince HM, Roberts A, et al. Consolidation therapy with thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single ASCT procedure. J Clin Oncol 2009;27:1788-1793.
24. Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with interphase cytogenetic abnormalities. Blood 2008;112:2999-3000[comment].
25. Morgan GJ, Jackson GH, Davies FE, et al. Maintenance thalidomide may improve progression free but not overall survival: results from the Myeloma IX maintenance randomization [abstract]. Blood 2008;112:Abstract 656.
26. Ladetto M, Pagliano G, Ferrero, et al. Major shrinking of residual tumor cell burden and achievement of molecular remissions in myeloma patients undergoing post-transplant consolidation with bortezomib, thalidomide and dexamethasone: a qualitative and quantitative PCR study [abstract]. Blood 2008;112:Abstract 3683.
27. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-436.
28. Cavo M, Zamagni, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-39. (Pubitemid 40967171)
29. Macro M, Divine M, Uzunban Y, et al. Dexamethasone + thalidomide compared to VAD as pre-transplant treatment in newly diagnosed multiple myeloma: a randomized trial [abstract]. Blood 2006;108:Abstract 22a.
30. Harousseau JL, Mathiot C, Attal M, et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem-cell transplantation in previously untreated multiple myeloma. Updated results from IFM 2005/01 trial [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 455s.
31. Rajkumar SV, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E403): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood 2007;110:Abstract 31a.
32. Mark T, Stern J, Furst JR, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 2008;14:795-798. (Pubitemid 351773154)
33. Lokhorst HM, Schidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial remission rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008;93:124-127.
34. Morgan GJ, Davies FE, Owen RG, et al. Thalidomide combinations improve response rates: results from the MRC IX study [abstract]. Blood 2007;110:Abstract 1051a.
35. Sonneveld P, van der Holt B, Schmidt-Wolf IGH, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM) [abstract]. Blood 2008;112:243-244. Abstract 653.
36. Cavo M, Tacchetti P, Patriarca F, et al. Superior complete response rate and progression-free survival after autologous transplantation with upfront velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Blood 2008;112:Abstract 65.
37. Pineda Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with Total Therapy 2. Br J Haematol 2008;140:625-634. (Pubitemid 351300910)
38. Palumbo A, Bringhen S, Liberati A, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma:updated results of a randomized, controlled trial. Blood 2008;112:3107-3114.
39. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;35:906-917.
40. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459-4465. (Pubitemid 350063804)
41. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin/Revlimid/ Dcxamethasone) combination therapy results in high complete and overall response rates in treatment-naive symptomatic multiple myeloma. Blood 2008;111:1101-1109. (Pubitemid 351213388)
42. Richardson PG, Lonial S, Jakubowiak S, et al. Safety and efficacy of lenalidomide, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 459s.
43. Harousseau JL. The allogeneic dilemma. Bone Marrow Transplant 2207;40:1123-1128.
44. Crawley C, Lalancette M, Szydlo R, et al. Outcomes of reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;105:4532-4539. (Pubitemid 40720805)
45. Crawley C, Iacobelli S, Björkstrand B, et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588-3594. (Pubitemid 46572554)
46. Rotta M, Storer BE, Sahebi F, et al. Long-term outcome of patients with multiple myeloma after autologous hematopietic cell transplantation and nonmyeloablative allografting Blood 2009;113:3383-3391.
47. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110-1120. (Pubitemid 46425595)
48. Moreau P, Garban F, Attal M, et al. Long-term follow-up results of IFM 99-03 and IFM 99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 2008;112:3914-3915.
49. Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective Pethema study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in multiple myeloma. Blood 2008;112:3591-3592.